Hoechst Marion Roussel Funds Outcomes Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 6
Volume 6
Issue 6

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grants totaling nearly $500,000 to fund health economics and outcomes studies through its 1997 ACCORD (A Company-wide Commitment to Outcomes Research and Development) program.

KANSAS CITY, Mo--Hoechst Marion Roussel is offering research grantstotaling nearly $500,000 to fund health economics and outcomes studiesthrough its 1997 ACCORD (A Company-wide Commitment to Outcomes Researchand Development) program.

Researchers and institutions interested in applying for grants can receivea program brochure and application form by calling ACCORD coordinator MaryMiller at 816-966-3780. The deadline for proposals is August 15, 1997.

Articles in this issue
Studies of Counselings' Impact on Survival Challenged
Telomerase Activity Potential Marker for Bladder Cancer
HIV Has Become a Specialty Disease, But One Open to the Well-Informed Generalist
Writing Genetic Testing Guidelines Complex Endeavor
AACR Meeting Sees Growth Spurt in Telomerase Research
DDT Appears to Activate Human Estrogen Receptors
Studies Highlight Role of bcl-2 Gene in Programmed Cell Death
Efficacy of BCG Maintenance in Bladder Cancer Is Confirmed
Surgery Seen as Adjunct to Chemo in Some Invasive Breast Cancers
Traveling Exhibit of Cancer Educational Resources
History of Substance Abuse Not a Barrier to Opioid Use
Support Program for Melanoma Patients Receiving Interferon
Taxol/Adriamycin as First-Line Metastatic Breast Cancer Therapy
New Cancer Websites, New Features Join the Information Highway
Dying in Hospital May Be Preferable to Dying at Home
Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
We’re helping to train healthcare professionals from some of these countries, at least on the clinical side, and giving them an idea of how manufacturing happens.

How Are Cellular Therapeutics Distributed in Global Oncology Settings?

Tim Cortese
October 16th 2025
Article

In lower- and middle-income countries, accessibility, cost, and talent are obstacles to broadly implementing cellular therapeutics into cancer care.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC

Roman Fabbricatore
October 16th 2025
Article

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

EO2463 combines 4 synthetic peptides that correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with CD20, CD22, CD37, and CD268, the B lymphocyte-specific lineage markers.

FDA Grants FTD to Novel Cancer Vaccine in Low Tumor Burden Follicular Lymphoma

Tim Cortese
October 16th 2025
Article

The EO2463 off-the-shelf immunotherapy achieved an overall response rate of 46% in patients with follicular lymphoma considered to be in the “watch-and-wait” setting.

The most common any-grade TRAEs were fatigue (56%), diarrhea (33%), maculopapular rash (30%), pruritus (22%), anemia (19%), arthralgia (19%), and decreased lymphocyte count (19%).

Single-Agent PD-1 Blockade Therapy Improves Responses in Desmoplastic Melanoma

Tim Cortese
October 15th 2025
Article

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.